Ironwood Pharmaceuticals (IRWD)
(Delayed Data from NSDQ)
$6.84 USD
+0.12 (1.79%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $6.83 -0.01 (-0.15%) 6:42 PM ET
4-Sell of 5 4
C Value B Growth B Momentum B VGM
Brokerage Reports
Ironwood Pharmaceuticals, Inc. [IRWD]
Reports for Purchase
Showing records 101 - 120 ( 1022 total )
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
3Q19 Financials Reported; Moderately Better Revenue Growth; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Biotechnology - Recent Drug Launch Weekly Retail Sales Tracker - Week Ended October 25
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Biotechnology - Recent Drug Launch Weekly Retail Sales Tracker - Week Ended October 18
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Recent Drug Launch Weekly Retail Sales Tracker
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
We are dropping coverage due to realignment of analyst resources
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Biotechnology - Recent Drug Launch Weekly Retail Sales Tracker - Week Ended August 23
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Retail Prescription Sales Tracker - Constipation Drugs
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Retail Prescription Sales Tracker - Constipation Drugs
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Biotechnology - Recent Drug Launch Weekly Retail Sales Tracker
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Retail Prescription Sales Tracker - Constipation Drugs
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Biotechnology - Recent Drug Launch Weekly Retail Sales Tracker
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
2Q19 Financial Results Reported; Revenue Guidance Maintained; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Biotechnology - Recent Drug Launch Weekly Retail Sales Tracker - Week Ended July 26
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Retail Prescription Sales Tracker - Constipation Drugs
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Q2:19; Positive Demand Growth and Profitability Weighed by Pricing Pressure
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D